Abstract. Rejection is still a major obstacle in long-term allograft survival of renal transplant recipients. Long non-coding RNAs (lncRNAs) are an important class of pervasive RNAs involved in a variety of biological functions, and which are often found to be differentially expressed between healthy and pathological conditions. The aim of this study was to compare the expression profiles of lncRNAs between samples from acute rejection following kidney transplantation and control samples. Three patients were enrolled, diagnosed by renal biopsy with acute rejection upon kidney transplantation. We used lncRNA microarrays to study the lncRNA expression profiles in the kidney biopsies of these patients and in kidneys from healthy donors. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to validate the microarray results. In addition, potential functions of the identified lncRNAs were further explored by searching the UCSC, RNAdb, RefSeq and NRED databases. Five candidate lncRNAs displaying differential expression in acute rejection samples were validated by RT-qPCR. The results were in agreement with the microarray data. Among the identified lncRNAs, certain have been previously identified in relevant conditions, thereby supporting previous evidence, but certain may constitute novel biomarker candidates. This is the first report to date using lncRNA microarrays to identify unique expression signatures of acute rejection in transplant biopsies. Our data indicate that lncRNAs are potentially involved in the pathogenesis of acute rejection. Our results may have important implications in the identification of diagnostic biomarkers, as well as in the understanding and treatment of acute rejection following renal transplantation.
Introduction
Renal transplantation is the best currently available therapy for patients with end-stage renal disease, since it results not only in better survival rates, but also, in better quality of life for the patients compared to dialysis. Rejection is still a major obstacle in long-term allograft survival in renal transplant recipients. The decrease in the incidence of clinical rejections and the increased graft survival at one year after transplantation do not improve the long-term outcome of renal transplant patients. Current rates of graft loss are in the order of 2% per year (1) . Numerous risk factors are known to influence graft survival, such as the age of the recipient, its ethnicity, diabetes, delayed graft function and human leukocyte antigen mismatch (2, 3) . Acute rejection (AR) has consistently been reported to be the most important immunologic risk factor leading to chronic allograft nephropathy (4) (5) (6) , which is also the most common cause of graft loss after the first year of transplantation (7, 8) . AR is a complex process of injury of the allograft, caused by infiltrating cells of the host immune system.
The diagnosis of acute renal allograft rejection is commonly based on the increase in the serum creatinine level, indicating renal injury. The ʻgold standardʼ for clinical diagnosis of acute rejection in patients with kidney transplants is based on histological classification of a graft biopsy, which is costly, invasive and entails risks of complications (9) (10) (11) (12) . In order to develop the most appropriate molecular diagnostic criteria, several research groups have employed '-omics' technologies, such as transcriptomics and proteomics, expected to allow identifying novel biomarkers and unravelling the biological mechanisms underlying acute rejection following transplantation (13) . In a previous study, our group identified 20 microRNAs (miRNAs) differentially expressed (DE) in acute rejection following renal transplantation. These data indicated that miRNAs are involved in the pathogenesis of acute rejection, and may be useful in diagnosis, treatment and prevention of acute rejection after renal transplantation (14) . Unfortunately, candidates from currently employed approaches do not fulfill the criteria for clinical application (15) . Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nt with little or no protein-coding capacity. LncRNAs can both up-and downregulate gene expression in eukaryotes and prokaryotes, and are essential in processes such as dosage compensation, genomic imprinting, developmental patterning and differentiation, and stress response (16) (17) (18) (19) (20) . Moreover, genome-wide studies on embryonic stem cells, adult brain, CD8 + T cells, and a number of other tissues have indicated that the few lncRNAs that have been characterized to date display a diverse range of functions, expression profiles in specific cell types and localizations in specific subcellular compartments (21) (22) (23) .
To date, the association between changes in expression of lncRNAs and acute rejection following renal transplantation has not been studied. In this study, we analyzed lncRNA expression in human renal allograft biopsies of acute rejection following renal transplantation using the Arraystar Human lncRNA arrays, and explored the association between lncRNAs and acute rejection upon renal transplantation.
Materials and methods
Patients and controls. We studied biopsies of three patients with acute rejection graded as IA and IB as per the Banff 97 classification (9) . Renal biopsies were performed by clinical ultrasound observation using the BIOPTYo instrument (BARD, Murray Hill, NJ, USA). The samples constituted of renal cortex, obtained from renal resection operation. Diagnosis of acute rejection in all patients was confirmed by histological tests, as described in the histological analysis. The 3 samples of the control group were renal cortex obtained during resection operation of the renal tumor; the samples located far from the tumor tissue, and tissue structures appeared normal under the light microscope. All biopsies were performed at the 181st Hospital of Guangxi Military Area of PLA from 2011 to 2012. The present study was approved by the Ethics Committee of the 181st Hospital Guangxi Military Area of PLA and written informed consent was obtained from each patient.
Histological analysis. The biopsy material was immediately fixed in 10% phosphate-buffered paraformaldehyde and stored at 4˚C. Following fixation, biopsies were dehydrated through passages in solutions of increasing ethanol concentration and were embedded in EPON 812 resin (Haide Biotech Company, Beijing, China). Serial, semi-thin (0.5-µm thick) sections were performed on a Reichert Ultracut Emicrotome (Leica, Glattbrugg, Switzerland). The resin was removed by treatment of the sections with sodium methoxide prior to rehydration, and immunostaining was performed as previously described (24 RNA isolation and target labeling. Total RNA was extracted using the Invitrogen™ TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) and the RNeasy kit (Qiagen, Hilden, Germany) following the manufacturer's instructions, including a DNase digestion step. Following measurement of the RNA concentration on the Nanodrop ND-1000 machine (NanoDrop Technologies, Wilmington, DE, USA) and denaturing gel electrophoresis, the samples were used to synthesize double-stranded cDNA using the Invitrogen™ Superscript ® Double-Stranded cDNA Synthesis kit (Thermo Fisher Scientific). cDNA synthesis was performed for 60 min at 37˚C. The cDNA was labeled using a biotinylated nucleotide in vitro labeling kit (Affymetrix, Santa Clara, CA, USA) and hybridized to the 12x135 K LncRNA Expression microarray using the NimbleGen Hybridization System (Roche Diagnostics, Shanghai, China).
Microarray expression analysis.
The microarray used in this study is designed for global profiling of long transcripts, including lncRNAs and protein-coding mRNAs. Each transcript is represented by 1-5 unique probes, in order to improve statistical confidence. Probes for housekeeping genes and negative probes are present multiple times to ensure hybridization quality. Human lncRNAs (n=18,534) in this microarray have been collected from multiple data sources, including the NCBI RefSeq database (db), the University of California, Santa Cruz (UCSC) Genome db, RNAdb (http://research.imb.uq.edu.au/ rnadb/), NRED (http:/nred.matticklab.com/cgi-bin/ncrnadb. pl), and the literature. Highly similar sequences and ncRNAs <200 bp are excluded. Protein-coding genes (n=18,847) from the NCBI RefSeq db are also contained on this array, to allow simultaneous detection of mRNAs and lncRNAs in a single experiment.
Raw data were extracted as pair files using the NimbleScan software version 2.5 (Roche Diagnostics). Quantile normalization and background correction were performed with the RMA method implemented in this software. The Probe level ( * _norm_ RMA.pair) files and the Gene summary ( * _RMA.calls) files were created. The 2 gene summary files were imported into the GeneSpring software version 11.0 (Agilent Technologies, Inc., Santa Clara, CA, USA) for further analysis. The effect of normalization was examined on box-plots. DE lncRNAs were identified by fold-change analysis and a p-value cutoff <0.05.
Pathway analysis of DE RNAs.
Pathway analysis was based on the pathways available at the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg/). This analysis allows to identify the biological pathways in which the differentially expressed RNAs are involved. The p-value denotes the significance of pathway enrichment based on Fisher tests: the lower the p-value, the more significantly enriched is the list of DE RNAs in this pathway. We used the recommended p-value cutoff ≤0.05.
Quantitative PCR (qPCR).
The qPCR reaction was carried out using 1 µl (50-100 ng/µl) of cDNA as the template; 1 µl of forward and reverse primers (listed in Table I ) and 10 µl of Invitrogen™ 10,000X SYBR-Green PCR Master mix (Thermo Fisher Scientific). The cDNA was serially diluted 2-fold in nuclease-free water prior to use. The experiment was conducted in duplicate for each sample. Master mix without total RNA was prepared for all reactions, and 24 µl were aliquoted into each reaction tube. The diluted cDNA was then added individually in each tube. qPCR reactions were conducted on a Rotor-Gene 3000 Real-Time PCR system (Corbett Research, New South Wales, Australia) as follows: pre-denaturation for 5 min at 95˚C; 40 cycles of 10 sec at 95˚C, 15 sec at 58˚C, and 20 sec at 72˚C. Melting-curve analysis was performed to determine the reaction specificity. Agarose gel electrophoresis was also performed to confirm of the size of the PCR products. The mean of the cycle threshold (Ct) values was calculated in order to determine the linearity of the GAPDH expression level. The expression data were analyzed with the comparative CT method (25) .
Statistical analysis. Signal intensities for each spot were acquired by the Axon GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA) and further analyzed with the NimbleScan and Agilent GeneSpring software. Signal intensities for each spot were calculated by subtracting the local background (based on the median intensity of the area surrounding each spot) from the total intensity. An average value of the 5 spot replicates for each lncRNA was generated following data transformation (to convert any negative value to 0.01), and normalization was performed by using a "per chip normalization", in which each measurement was divided by the 50th percentile of all measurements in its array, allowing comparison among chips. In order to identify lncRNAs that characterize each group, a per-gene median normalization was performed, which normalizes the expression of every lncRNA on its median among samples.
Results
RNA quantity and quality. The quantity and quality of the acute rejection (AR) and normal (healthy) control (NC) RNA samples were assessed by gel electrophoresis (Fig. 1) and via the optical density ratio OD 260 /OD 280 (Table II) . These analyses confirmed that the isolated total RNA is of good quality.
LncRNA expression. To compare the expression profiles of lncRNAs in AR and NC samples, we used a custom microarray approach. Following normalization of the raw data, the differentially expressed genes or lncRNAs were identified based on fold-change differences in expression between the two groups, with a threshold value ≥2.0. This analysis identified 5,339 lncRNAs as significantly differentially expressed. Of these, 2,191 lncRNAs were found to be upregul ated and 3,148 to be downregulated. The top 20 upregulated and downregulated lncRNAs in AR samples as compared to NC samples are summarized in Table III . From the DE lncRNAs, we selected, based on their fold changes and probability values, 5 for validation by RT-qPCR, which confirmed their expression profiles (Table IV) . suggest that alterations in expression of a limited number of genes may affect the regulation of numerous immune response and inflammatory pathways that are common to acute rejection.
Discussion
High-density microarray technology provides a means to simultaneously measure the differential expression of hundreds to thousands of genes. The ability to measure the expression of lncRNAs in samples of early acute rejection following kidney transplantation allows to identify several biomarkers that have the potential to directly impact current clinical practices. In the present study, we took advantage of the high-throughput nature of the Arraystar Human lncRNA array to identify and characterize lncRNAs differentially expressed between acute rejection following renal transplantation and healthy control tissues. This study identified 5,339 DE lncRNAs, of which 3,148 were downregulated and 2,191 were upregulated in AR compared to NC samples. From the functional analysis of these DE lncRNAs using KEGG pathway enrichment (13, 26) . As immune cells, such as T cells, differentiate, gene expression is affected by the combination of epigenetic alterations in DNA methylation, chromatin structure and locus accessibility (27) . The roles of lncRNAs in gene and epigenetic regulation are well documented (28) . The finding of the present study that thousands of lncRNAs are expressed in acute renal rejection is not surprising. In addition, the presented data are derived from only three patients.
The function of only a minority of lncRNAs is documented at present. Therefore, we studied the potential association between acute rejection and lncRNAs in order to gain new insights into the pathogenesis of acute rejection and potentially identify novel biomarkers, which are aspects that have not been previously studied. From the DE lncRNAs identified herein, we selected 5 based on their expression fold changes and probability values for further validation by RT-qPCR experiments, and further investigated their functions in the literature.
The lncRNA uc001fty locates at the intron of the C-reactive protein-coding gene (CRP). LncRNAs from introns have diverse regulatory functions, such as acting as precursors of shorter RNAs, protein-coding RNA stabilization, control of gene expression, and regulation of alternative splicing in protein-coding RNA (29) . The uc001fty belongs to the pentaxin family. It is involved in several host defense-related functions based on its ability to recognize foreign pathogens and host damaged cells and to initiate their elimination by interacting with humoral and cellular effector systems in the blood. In our study, we observed downregulation in both uc001fty and CRP gene expression. T cells play a key role in the alloimmune response, thus it is not surprising that TCR active-chain expression was upregulated in all acute rejection samples (data not shown), as previously shown by other groups (7) (8) (9) . The uc003wbj, corresponding to the Homo sapiens mRNA for the T-cell receptor β chain, was found at relatively high expression level in the acute rejection samples, which may be related with inflammatory reactions occurring during acute rejection.
Transcribed lncRNAs interact with downstream promoter regions of protein-coding genes to regulate mRNA expression (30) . The lncRNA AK129917 (chr2, mRNA) locates across the transcription start site of Hsp90B. Hsp90 proteins are highly conserved molecular chaperones that have key roles in signal transduction, protein folding, protein degradation and morphology. Overexpression of Hsp90s has been reported in rat renal cortex following ischemia and in recipients with graft-versus-host disease (31, 32) . Interestingly, we observed that AK129917 and Hsp90B1 are both upregulated in acute rejection biopsy samples, possibly through independent regulation pathways.
The lncRNA uc010ftb (chr6, UCSC) locates across the transcription start site of the caspase 10 gene (CASP10). This lncRNA encodes a protein that is a member of the cysteineaspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution phase of cell apoptosis. In this study, we found that CASP10 is downregulated, but the expression of uc010ftb was upregulated. From these data, we may infer that uc010ftb negatively regulates the CASP10 gene. The lncRNA AF113674 (chr19, mRNA) also locates across the transcription start site of the complement component 3 (C3). The complement system is an important contributor to both innate and adaptive immunity, ultimately forming a proteolytic cascade that sets an inflammatory reaction in motion. Innate immunity, adaptive immunity and inflammation all converge at the C3 convertase step, a central amplification point in the cascade (33) . The activation of the complement is associated with ischemia, reperfusion and inflammation that occur during graft rejection (34) . Therefore, the AF113674 lncRNA may constitute a suitable biomarker of acute rejection.
The individual lncRNA variation between patients may be difficult to detect and of no significance, since random expression changes may occur in each patient. In our study, RNAs from each group were pooled together in the same sample, so that the individual differences among subjects are reduced. The aim of this study was to reveal the relationship between acute renal rejection and lncRNAs, expecting to draw the attention of additional research groups to this subject.
In conclusion, we presented herein an analysis of lncRNA expression in control and acute rejection renal allograft biopsy samples using lncRNA microarrays. Our results indicate that certain lncRNAs show promising potential as diagnostic biomarkers and as factors involved in the pathogenesis of acute rejection. Nevertheless, it is important to note that the findings described in this study are merely a starting point for the understanding of roles that lncRNAs may play in acute renal transplant rejection. In this context, it is notable that the function of only a minority of lncRNAs is documented at present. Additional studies are needed to functionally characterize lncRNAs, including the ones identified in this study. The list of lncRNAs linked to acute rejection following renal transplantation may promote the identification of novel methods for the diagnosis, treatment and prevention of acute renal rejection, and further illuminate the mechanisms underlying the rejection of other solid organ transplants.
